Commitment to Action

Gardasil® Access Program

Commitment by

Merck & Co., Inc.

In 2007, through the GARDASIL Access Program, Merck and Co., Inc. (Merck) committed to donate at least three million doses of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] to organizations and institutions in developing countries, where approximately 85% of the world's cervical cancer cases occur. Since inception, The GARDASIL Access Program has donated more than one million doses of GARDASIL - enough to vaccinate more than 342,000 eligible girls - which enabled organizations and institutions in 20 eligible lowest income countries to implement small scale HPV vaccination projects.

Share

Tabs

Overview
Summary

Commitment

Gardasil® Access Program

Launched

2007

Est. Duration

5 Years

Estimated Total Value

$375,500,000

Region

Asia, Latin America & Caribbean, Africa

Countries

BHUTAN, BOLIVIA, CAMBODIA, CAMEROON, GEORGIA, GHANA, GUYANA, HAITI, HONDURAS, INDIA

Commitment by

Merck & Co., Inc.